Published in J Immunol on May 01, 1988
Preclinical in vitro and in vivo activity of 5,6-dimethylxanthenone-4-acetic acid. Br J Cancer (1995) 0.97
Flavone acetic acid--an interesting novel therapeutic agent or just another disappointment? Br J Cancer (1991) 0.93
Flavone acetic acid (FAA) with recombinant interleukin-2 (TIL-2) in advanced malignant melanoma. II: Induction of nitric oxide production. Br J Cancer (1992) 0.89
Recombinant interleukin-2 (rIL-2) given intrasplenically and intravenously for advanced malignant melanoma. A phase I and II study. Br J Cancer (1989) 0.87
Flavone acetic acid (FAA) with recombinant interleukin-2 (rIL-2) in advanced malignant melanoma. III: Cytokine studies. Br J Cancer (1993) 0.87
Flavone acetic acid (FAA) with recombinant interleukin-2 (rIL-2) in advanced malignant melanoma: I. Clinical and vascular studies. Br J Cancer (1993) 0.84
Recombinant interleukin-2 (rIL-2) with flavone acetic acid (FAA) in advanced malignant melanoma: a phase II study. Br J Cancer (1990) 0.80
Flavone acetic acid (FAA) with recombinant interleukin-2 (rIL-2) in advanced malignant melanoma. IV: Pharmacokinetics and toxicity of flavone acetic acid and its metabolites. Br J Cancer (1993) 0.79
Differential efficacy of flavone acetic against liver versus lung metastases in a human tumour xenograft. Br J Cancer (1991) 0.78
Tumour concentrations of flavone acetic acid (FAA) in human melanoma: comparison with mouse data. Br J Cancer (1992) 0.75
Recombinant interleukin-2 (rIL-2) with flavone acetic acid (FAA) in advanced malignant melanoma: immunological studies. Br J Cancer (1990) 0.75
New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst (1990) 23.46
Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res (1988) 9.96
Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res (1988) 8.53
Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J Natl Cancer Inst (1989) 4.97
Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines. J Natl Cancer Inst (1990) 4.08
New soluble-formazan assay for HIV-1 cytopathic effects: application to high-flux screening of synthetic and natural products for AIDS-antiviral activity. J Natl Cancer Inst (1989) 4.04
Prostratin: activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART. Blood (2001) 2.88
Morphological and immunocytochemical characteristics of human tumor cell lines for use in a disease-oriented anticancer drug screen. Anticancer Res (1992) 2.62
Solution structure of cyanovirin-N, a potent HIV-inactivating protein. Nat Struct Biol (1998) 2.19
Antiherpesvirus activity of 9-(4-hydroxy-3-hydroxy-methylbut-1-yl)guanine (BRL 39123) in cell culture. Antimicrob Agents Chemother (1987) 2.11
Tetrazolium-based assays for cellular viability: a critical examination of selected parameters affecting formazan production. Cancer Res (1991) 2.06
Antineoplastic agents. 291. Isolation and synthesis of combretastatins A-4, A-5, and A-6(1a) J Med Chem (1995) 1.98
Development of human tumor cell line panels for use in disease-oriented drug screening. Prog Clin Biol Res (1988) 1.95
The calanolides, a novel HIV-inhibitory class of coumarin derivatives from the tropical rainforest tree, Calophyllum lanigerum. J Med Chem (1992) 1.89
Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation. J Clin Invest (1998) 1.61
Crystal structure of cyanovirin-N, a potent HIV-inactivating protein, shows unexpected domain swapping. J Mol Biol (1999) 1.57
Cytotoxic geranyl stilbenes from Macaranga schweinfurthii. J Nat Prod (1998) 1.50
Selection of an oral prodrug (BRL 42810; famciclovir) for the antiherpesvirus agent BRL 39123 [9-(4-hydroxy-3-hydroxymethylbut-l-yl)guanine; penciclovir]. Antimicrob Agents Chemother (1989) 1.48
Antineoplastic agents 322. synthesis of combretastatin A-4 prodrugs. Anticancer Drug Des (1995) 1.46
Analysis of nonnucleoside drug-resistant variants of human immunodeficiency virus type 1 reverse transcriptase. J Virol (1993) 1.41
Evidence for the Clara cell as a site of cytochrome P450-dependent mixed-function oxidase activity in lung. Nature (1977) 1.41
Administration of recombinant human IL-7 to mice alters the composition of B-lineage cells and T cell subsets, enhances T cell function, and induces regression of established metastases. J Immunol (1994) 1.39
Isolation and structure of the cell growth inhibitory constituents from the western Pacific marine sponge Axinella sp. J Med Chem (1991) 1.32
Cyanovirin-N defines a new class of antiviral agent targeting N-linked, high-mannose glycans in an oligosaccharide-specific manner. Mol Pharmacol (2001) 1.31
IFN-gamma and Fas/FasL are required for the antitumor and antiangiogenic effects of IL-12/pulse IL-2 therapy. J Clin Invest (2001) 1.30
Administration of interleukin 12 with pulse interleukin 2 and the rapid and complete eradication of murine renal carcinoma. J Natl Cancer Inst (1996) 1.29
Extrapulmonary, tissue-specific metastasis formation in nude mice injected with FEMX-I human melanoma cells. Cancer Res (1988) 1.29
Selective interactions of the human immunodeficiency virus-inactivating protein cyanovirin-N with high-mannose oligosaccharides on gp120 and other glycoproteins. J Pharmacol Exp Ther (2001) 1.28
Antineoplastic agents, 256. Cell growth inhibitory isocarbostyrils from Hymenocallis. J Nat Prod (1993) 1.26
Antireplicative and anticytopathic activities of prostratin, a non-tumor-promoting phorbol ester, against human immunodeficiency virus (HIV). Antiviral Res (1997) 1.26
Crystal structure of Escherichia coli HdeA. Nat Struct Biol (1998) 1.25
Oxathiin carboxanilide, a potent inhibitor of human immunodeficiency virus reproduction. Proc Natl Acad Sci U S A (1991) 1.24
Antineoplastic agents. 379. Synthesis of phenstatin phosphate. J Med Chem (1998) 1.23
A semiautomated multiparameter approach for anti-HIV drug screening. J Virol Methods (1991) 1.21
HIV inhibitory natural products. 26. Quinoline alkaloids from Euodia roxburghiana. J Nat Prod (1996) 1.19
HIV-inhibitory cembrane derivatives from a Philippines collection of the soft coral Lobophytum species. J Nat Prod (2000) 1.18
Acute pulmonary injury in rats by nitrofurantoin and modification by vitamin E, dietary fat, and oxygen. Am Rev Respir Dis (1979) 1.18
Penciclovir is a selective inhibitor of hepatitis B virus replication in cultured human hepatoblastoma cells. Antimicrob Agents Chemother (1996) 1.17
Lack of correlation between natural killer activity and tumor growth control in nude mice with different immune defects. Cancer Res (1984) 1.15
Comparative anti-HIV evaluation of diverse HIV-1-specific reverse transcriptase inhibitor-resistant virus isolates demonstrates the existence of distinct phenotypic subgroups. Antiviral Res (1995) 1.14
Profiles of prostaglandin biosynthesis in normal lung and tumor tissue from lung cancer patients. Cancer Res (1988) 1.13
AIDS-antiviral sulfolipids from cyanobacteria (blue-green algae). J Natl Cancer Inst (1989) 1.12
Thiazolinone analogues of indolmycin with antiviral and antibacterial activity. J Med Chem (1978) 1.10
Multidrug-resistant phenotype of disease-oriented panels of human tumor cell lines used for anticancer drug screening. Cancer Res (1992) 1.10
Antineoplastic agents 430. Isolation and structure of cribrostatins 3, 4, and 5 from the republic of maldives cribrochalina species. J Nat Prod (2000) 1.10
A chemical screening strategy for the dereplication and prioritization of HIV-inhibitory aqueous natural products extracts. J Nat Prod (1993) 1.10
Guttiferone F, the first prenylated benzophenone from Allanblackia stuhlmannii. J Nat Prod (1999) 1.09
Analysis of the interaction between the HIV-inactivating protein cyanovirin-N and soluble forms of the envelope glycoproteins gp120 and gp41. Mol Pharmacol (2000) 1.09
Correlation between in vivo induction of cytokine gene expression by flavone acetic acid and strict dose dependency and therapeutic efficacy against murine renal cancer. Cancer Res (1990) 1.08
Siamenol, a new carbazole alkaloid from Murraya siamensis. J Nat Prod (2000) 1.07
Antineoplastic agents. 398. Isolation and structure elucidation of cephalostatins 18 and 19. J Nat Prod (1998) 1.06
Haligramides A and B, two new cytotoxic hexapeptides from the marine sponge Haliclona nigra. J Nat Prod (2000) 1.05
A pentahalogenated monoterpene from the red alga Portieria hornemannii produces a novel cytotoxicity profile against a diverse panel of human tumor cell lines. J Med Chem (1992) 1.05
Antineoplastic agents 365. Dolastatin 10 SAR probes. Anticancer Drug Des (1998) 1.04
Studies directed towards the refinement of the pancratistatin cytotoxic pharmacophore. Bioorg Med Chem Lett (2001) 1.04
In vitro metabolic activation of the pulmonary toxin, 4-ipomeanol, in nonciliated bronchiolar epithelial (Clara) and alveolar type II cells isolated from rabbit lung. J Pharmacol Exp Ther (1982) 1.03
Cytokine-mediated protection of human dendritic cells from prostate cancer-induced apoptosis is regulated by the Bcl-2 family of proteins. Br J Cancer (2000) 1.03
Morphometric and colorimetric analyses of human tumor cell line growth and drug sensitivity in soft agar culture. Cancer Res (1991) 1.03
Activity of mitozolomide (NSC 353451), a new imidazotetrazine, against xenografts from human melanomas, sarcomas, and lung and colon carcinomas. Cancer Res (1985) 1.03
Prodrugs of the selective antiherpesvirus agent 9-[4-hydroxy-3-(hydroxymethyl)but-1-yl]guanine (BRL 39123) with improved gastrointestinal absorption properties. J Med Chem (1989) 1.03
Ethnobotany and drug discovery: the experience of the US National Cancer Institute. Ciba Found Symp (1994) 1.03
Solution structure by NMR of circulin A: a macrocyclic knotted peptide having anti-HIV activity. J Mol Biol (1999) 1.02
Recombinant production of cyanovirin-N, a potent human immunodeficiency virus-inactivating protein derived from a cultured cyanobacterium. Protein Expr Purif (1998) 1.02
Biochemical mechanisms in chemical-induced lung injury: roles of metabolic activation. Crit Rev Toxicol (1980) 1.02
Specific inhibition of the reverse transcriptase of human immunodeficiency virus type 1 and the chimeric enzymes of human immunodeficiency virus type 1 and type 2 by nonnucleoside inhibitors. Antimicrob Agents Chemother (1993) 1.01
Confirmation by chemical synthesis of the structure of 4-ipomeanol, a lung-toxic metabolite of the sweet potato, Ipomoea batatas. Nat New Biol (1972) 1.01
Anti-HIV prenylated flavonoids from Monotes africanus. J Nat Prod (2001) 1.00
Isolation, primary sequence determination, and disulfide bond structure of cyanovirin-N, an anti-HIV (human immunodeficiency virus) protein from the cyanobacterium Nostoc ellipsosporum. Biochem Biophys Res Commun (1997) 1.00
New cytotoxic isomalabaricane triterpenes from the sponge Jaspis species. J Nat Prod (2001) 0.99
Phase I and pharmacological study of the pulmonary cytotoxin 4-ipomeanol on a single dose schedule in lung cancer patients: hepatotoxicity is dose limiting in humans. Cancer Res (1993) 0.99
Precursor phenotype of lymphokine-activated killer cells in the mouse. J Immunol (1987) 0.98
Superoxide and hydrogen peroxide production and NADPH oxidation stimulated by nitrofurantoin in lung microsomes: possible implications for toxicity. Life Sci (1979) 0.98
Protein thiol oxidation by haloperidol results in inhibition of mitochondrial complex I in brain regions: comparison with atypical antipsychotics. Neurochem Int (2001) 0.98
Pulmonary bronchiolar alkylation and necrosis by 3-methylfuran, a naturally occurring potential atmospheric contaminant. Nature (1978) 0.98
Antineoplastic agents 320: synthesis of a practical pancratistatin prodrug. Anticancer Drug Des (1995) 0.97
Comparison of intrapulmonary, percutaneous intrathoracic, and subcutaneous models for the propagation of human pulmonary and nonpulmonary cancer cell lines in athymic nude mice. Cancer Res (1988) 0.97
Successful treatment of advanced murine renal cell cancer by bicompartmental adoptive chemoimmunotherapy. J Immunol (1987) 0.97
Biological and biochemical anti-HIV activity of the benzothiadiazine class of nonnucleoside reverse transcriptase inhibitors. Antiviral Res (1994) 0.97
Engraftment and activity of anti-CD3-activated human peripheral blood lymphocytes transferred into mice with severe combined immune deficiency. J Immunol (1993) 0.97
Induction of brain cytochrome P-450IIE1 by chronic ethanol treatment. Brain Res (1993) 0.96
The activity of iododeoxyuridine, adenine arabinoside, cytosine arabinoside, ribavirin and phosphonoacetic acid against herpes virus in the hairless mouse model. J Antimicrob Chemother (1977) 0.96
Comparative activity of penciclovir and acyclovir in mice infected intraperitoneally with herpes simplex virus type 1 SC16. Antimicrob Agents Chemother (1993) 0.96
New cytotoxic N-methylated beta-carboline alkaloids from the marine ascidian Eudistoma gilboverde. J Nat Prod (2001) 0.96
Human Influenza Viruses in Domesticated Animals. Br Med J (1962) 0.96
Cyanovirin-N, a potent human immunodeficiency virus-inactivating protein, blocks both CD4-dependent and CD4-independent binding of soluble gp120 (sgp120) to target cells, inhibits sCD4-induced binding of sgp120 to cell-associated CXCR4, and dissociates bound sgp120 from target cells. Antimicrob Agents Chemother (2001) 0.95
Antineoplastic agents 337. Synthesis of dolastatin 10 structural modifications. Anticancer Drug Des (1995) 0.95
Cytotoxic and tubulin-interactive hemiasterlins from Auletta sp. and Siphonochalina spp. sponges. Bioorg Med Chem (1999) 0.95
Reactive metabolites from the bioactivation of toxic methylfurans. Science (1984) 0.95
The HIV-inactivating protein, cyanovirin-N, does not block gp120-mediated virus-to-cell binding. Biochem Biophys Res Commun (1998) 0.95
Activity of penciclovir in antiviral assays against herpes simplex virus. J Antimicrob Chemother (1996) 0.94
Immunomodulation of natural killer activity by polyribonucleotides. J Biol Response Mod (1985) 0.94
Structure-activity requirements for flavone cytotoxicity and binding to tubulin. J Med Chem (1998) 0.94
Antiviral activity and mechanism of action of calanolide A against the human immunodeficiency virus type-1. J Pharmacol Exp Ther (1996) 0.94
Analysis of sequence requirements for biological activity of cyanovirin-N, a potent HIV (human immunodeficiency virus)-inactivating protein. Biochem Biophys Res Commun (1997) 0.93
A novel anti-HIV macrocyclic peptide from Palicourea condensata. J Nat Prod (2001) 0.93
Antineoplastic agents. 362. Isolation and X-ray crystal structure of dibromophakellstatin from the Indian ocean sponge Phakellia mauritiana. J Nat Prod (1997) 0.92